Valuation: Galapagos NV

Market Cap 177.26Cr 202.77Cr 162.9Cr 151.85Cr 288.01Cr 19TCr 292.38Cr 1.96TCr 760.27Cr 9.49TCr 761.12Cr 744.78Cr 33TCr P/E 2026 *
-9.25x
P/E 2027 * -10.7x
Enterprise Value -88Cr -100.87Cr -81Cr -76Cr -143.27Cr -9.6TCr -145.45Cr -972.89Cr -378.21Cr -4.72TCr -378.63Cr -370.5Cr -16TCr EV / Sales 2026 *
-5.86x
EV / Sales 2027 * -5.09x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 13/05/2025
Director of Finance/CFO 43 07/07/2025
Chief Tech/Sci/R&D Officer 61 08/06/2026
Director TitleAgeSince
Director/Board Member 63 22/10/2019
Director/Board Member 49 07/10/2024
Director/Board Member 53 13/05/2025
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 202.77Cr
+0.28%+7.26%+3.73%+9.54% 4.99TCr
+0.30%-0.97%+420.18%+628.05% 4.02TCr
-1.25%+5.33%+25.32%-6.46% 3.46TCr
+4.01%+7.71%+29.61%+64.88% 3.31TCr
+3.96%+10.67%+8.30%+37.95% 2.75TCr
-2.16%+3.16% - - 1.7TCr
-1.56%+2.69%+72.19%+134.68% 1.59TCr
-0.46%+1.32%+14.60%+22.27% 1.39TCr
-0.24%+1.38%+95.80%+95.89% 1.35TCr
Average +0.39%+5.82%+83.72%+123.35% 2.73TCr
Weighted average by Cap. +0.71%+6.53%+95.45%+141.99%

Financials

2026 *2027 *
Net sales 15Cr 17Cr 14Cr 13Cr 24Cr 1.64TCr 25Cr 166Cr 65Cr 805.55Cr 65Cr 63Cr 2.78TCr 13Cr 15Cr 12Cr 11Cr 21Cr 1.44TCr 22Cr 145.76Cr 57Cr 707.31Cr 57Cr 56Cr 2.44TCr
Net income -26Cr -30Cr -24Cr -22Cr -42Cr -2.84TCr -43Cr -287.67Cr -111.83Cr -1.4TCr -111.95Cr -109.55Cr -4.81TCr -15Cr -17Cr -13Cr -12Cr -24Cr -1.58TCr -24Cr -160.16Cr -62Cr -777.21Cr -62Cr -61Cr -2.68TCr
Net Debt -265.44Cr -303.64Cr -243.94Cr -227.38Cr -431.28Cr -29TCr -437.82Cr -2.93TCr -1.14TCr -14TCr -1.14TCr -1.12TCr -49TCr -244.49Cr -279.67Cr -224.69Cr -209.43Cr -397.24Cr -27TCr -403.26Cr -2.7TCr -1.05TCr -13TCr -1.05TCr -1.03TCr -45TCr
Logo Galapagos NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
-
Trader
Investor
-
Global
-
Quality
ESG MSCI
B